Asymmetrical Dimethylarginine (ADMA) Antibody
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
Description
Polyclonal Antibody to Asymmetrical Dimethylarginine (ADMA).
Documents del producto
Product specifications
| Category | Primary Antibodies |
| Immunogen Target | Asymmetrical Dimethylarginine (ADMA) |
| Host | Rabbit |
| Reactivity | General |
| Recommended Dilution | IHC: 5-20 µg/ml, IF/ICC: 5-20 µg/ml. Optimal dilutions/concentrations should be determined by the end user. |
| Clonality | Polyclonal |
| Conjugation | Unconjugated |
| Purification | Purified by antigen-specific affinity chromatography, followed by Protein A affinity chromatography. |
| Size 1 | 100 µl |
| Size 2 | 200 µl |
| Size 3 | 1 ml |
| Form | Liquid |
| Tested Applications | IHC, IF/ICC |
| Buffer | 0.01 M PBS, pH 7.4, containing 0.05% Proclin-300, 50% glycerol. |
| Availability | Shipped within 5-7 working days. |
| Storage | Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
| Dry Ice | No |
| Alias | ADMA |
| Background | Antibody anti-ADMA |
| Status | RUO |
Descripción
Asymmetrical dimethylarginine (ADMA) is an endogenous molecule that competitively inhibits nitric oxide synthase (NOS), thereby reducing nitric oxide (NO) production and impairing vascular tone, endothelial function, and blood flow. As a key regulator of NO bioavailability, ADMA is a critical factor in cardiovascular health. Elevated ADMA levels are associated with endothelial dysfunction, hypertension, atherosclerosis, and heart failure, as insufficient NO contributes to inflammation, vascular rigidity, and oxidative stress. ADMA is metabolized by dimethylarginine dimethylaminohydrolase (DDAH), and any imbalance between ADMA production and clearance affects vascular and metabolic health. Beyond cardiovascular diseases, ADMA dysregulation is linked to chronic kidney disease, diabetes, and neurodegenerative disorders. ADMA serves as a biomarker for assessing cardiovascular and metabolic risks, and targeting the DDAH-ADMA-NO pathway is an emerging strategy to restore endothelial health and reduce vascular inflammation.
Related Products
Asymmetrical Dimethylarginine (ADMA) Antibody
Polyclonal Antibody to Asymmetrical Dimethylarginine (ADMA).
Ver Producto
Asymmetrical Dimethylarginine (ADMA) ELISA Kit
Asymmetrical Dimethylarginine (ADMA) ELISA Kit is an ELISA Kit for the in vitro quantitative measurement of Asymmetrical Dimethylarginine (ADMA) concentrations in serum, plasma, tissue homogenates, cell lysates, cell culture supernatants and other biological fluids. This assay has high sensitivity and excellent specificity for detection of Asymmetrical Dimethylarginine (ADMA)
Ver Producto
Asymmetrical Dimethylarginine (ADMA) ELISA Kit
Asymmetrical Dimethylarginine (ADMA) ELISA Kit is an ELISA Kit for the in vitro quantitative measurement of Asymmetrical Dimethylarginine (ADMA) concentrations in serum, plasma, tissue homogenates, cell lysates, cell culture supernatant and other biological fluids.
Ver Producto